Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Clinical protocol for early treatment of COVID-19 in a real-world scenario: Results of a series of patients
Sobrinho et al., Medicina Clínica Práctica, doi:10.1016/j.mcpsp.2022.100346
Sobrinho et al., Clinical protocol for early treatment of COVID-19 in a real-world scenario: Results of a series of patients, Medicina Clínica Práctica, doi:10.1016/j.mcpsp.2022.100346
Sep 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 116 patients between May and September 2020 in Brazil receiving an early treatment protocol including ivermectin and azithromycin, showing no mortality compared to up to 5.7% CFR in Brazil during the study period.
Sobrinho et al., 22 Sep 2022, Brazil, peer-reviewed, mean age 48.0, 4 authors, study period May 2020 - September 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Medicina Clínica Práctica 5 (2022) 100346 www.elsevier.es/medicinaclinicapractica Original Clinical protocol for early treatment of COVID-19 in a real-world scenario: Results of a series of patients Silvestre Sobrinho a,⁎, Fabiana Perrone a, Guilherme Montal b, Aroldo Bacellarc a b c Department of Internal Medicine and Emergency Service, Hospital da Cidade, Salvador, BA, Brazil University Hospital Prof. Edgard Santos, Salvador, Brazil Monte Tabor Foundation, Hospital São Rafael, Salvador, Brazil a r t i c l e in f o a b s t r a c t Article history: Received 10 July 2022 Accepted 11 September 2022 Available online 22 September 2022 Introduction: Despite the advance in vaccination, the SARS-CoV-2 infection remains a challenge for the medical community. Outpatient and hospital therapy for COVID-19 are still improving. Our study aimed to report the results of a series of patients with COVID-19 who participated in an outpatient treatment protocol since the first clinical manifestation. Methods: A case series report of individuals aged ≥18 years with clinical symptoms and a confirmed test for COVID-19 submitted to a treatment protocol. Patients were enrolled between May and September 2020 and followed for at least 15 days. The assessed clinical outcomes were the need for hospitalization, admission to the intensive care unit, orotracheal intubation, and death. Results: We studied a 116 patients. The mean age was 48 ± 14 years. Females formed 53%. The main comorbidities wereobesity (15.5%), systemic arterial hypertension (10.3%) ,type II diabetes (6%), and lung diseases (6.0%). Temperature N 37.7 °C (51.7%), cough (55.2%), myalgia (37.1%), headache (37.9%), and fatigue (34.5%) were the most frequent signs and symptoms. According to different disease staging, the most administered drugs were: azithromycin, ivermectin, corticosteroid, antibiotics, and anticoagulants. There was no death, and hospitalization accounted for only 8.6% of the patients (1 in ICU); none required orotracheal intubation. The mean length of hospital stay was 5.8 days. © 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the license CC BY-NC-ND (http:// creativecommons.org/licenses/by-nc-nd/4.0/). Keywords: COVID-19 Treatment protocol Ivermectin Corticosteroid Anticoagulant Protocolo Clínico para el Tratamiento Precoz de la COVID-19 en un escenario real: resultados de una serie de pacientes r e s u m e n Palabras clave: COVID -19 Protocolo de tratamiento Ivermectina corticoide anticoagulanteducción Introducción: a pesar del avance en la vacunación, la infección por SARS-CoV-2 sigue siendo un desafío para la comunidad médica. La terapia ambulatoria y hospitalaria para COVID-19 sigue mejorando. Nuestro estudio tuvo como objetivo informar los resultados de una serie de pacientes con COVID-19 que participaron en un protocolo de tratamiento ambulatorio desde la primera manifestación clínica. Métodos: estudio prospectivo con reportes de casos de personas ≥ 18 años con síntomas clínicos y pruebas confirmadas de COVID-19 en protocolo de tratamiento. Los pacientes se trataron consecutivamente entre mayo y septiembre de 2020 y se les dio seguimiento durante al menos 15 días. Los desenlaces clínicos evaluados fueron: la necesidad de hospitalización, la unidad de cuidados intensivos, la intubación orotraqueal y la muerte. Resultados: se estudiaron 116 pacientes. La edad media fue de 48 ± 14 años. Las hembras formaron el 53%. Las principales..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit